Northwest Bio received good news from Germany in February but didn't tell investors until Monday.
Investors in a biotech stock bubble whistle past legitimate concerns about La Jolla's GCS-100.
A closer look at the interim analyses for two cancer vaccine trials reveals potential problems.
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
A preview of the April 1 FDA advisory panel convened to review MannKind's inhaled insulin device.
Synta isn't saying why Safi Bahcall resigned as CEO but the stock has severely underperformed the market for the past year.
Drug approvals, FDA advisory panels and clinical trial results all on tap over the next 30 days.
Twelve weeks have passed since Northwest Bio said an interim analysis of the DCVax phase III study was underway. Where are the results?
An epic month of biotech stock performance ends with a significant sell off.
If history repeats, investor optimism for NewLink's phase III study is misplaced.